Monoclonal expects to be hit by an injunction.

Monoclonal Antibodies Inc. and Eli Lilly & Co. said they expect a U.S. District judge in San Francisco to issue a preliminary injunction within 10 days that will bar Mountain View, Calif.-based MAI from selling or manufacturing diagnostic products that account for about 80% of its revenue. MAI said it will comply with the court order. Lilly said the MAI products, which include pregnancy and ovulation diagnostic kits, infringe on patents held by its San Diego-based Hybritech Inc. subsidiary. The patents were upheld last fall by a federal appeals court in Washington.